Coccidioidomycosis Diagnostic Delays Stretch Across Outpatient Care
A large U.S. claims analysis found that coccidioidomycosis is frequently recognized late, with the average diagnostic delay approaching one month. Almost 60% of patients experienced at least one missed opportunity for diagnosis, a finding that fits the disease’s protean presentation and the way it masquerades as routine respiratory illness.
The delay is not a minor bookkeeping problem. When a fungal infection presents with cough, fever, chills, shortness of breath, chest discomfort, or fatigue, the first clinical instinct often points toward viral syndromes, bacterial pneumonia, or another common pulmonary process. In regions where clinicians do not see coccidioidomycosis every day, that overlap can easily redirect care away from the right test and toward repeated empiric treatment.
A One-Month Lag Before the Right Diagnosis
Using longitudinal insurance claims from the Merative MarketScan Databases, investigators examined U.S. encounters from 2001 through 2022. The cohort included Commercial and Medicare data from 2001–2022 and Multi-State Medicaid data from 2014–2021, giving the analysis a broad view of routine care across inpatient, outpatient, and emergency department settings.
The central estimate was stark: the average diagnostic delay was 29.69 days, with a 95% confidence interval of 28.25 to 31.18 days. Missed opportunities were identified predominantly in outpatient settings, where 73% of them occurred. In practical terms, the disease was not mainly slipping through hospital wards or emergency departments; it was being missed in the slower, more repetitive rhythms of ambulatory care, where patients may cycle through visits before anyone connects the symptoms to an endemic fungal infection.
A single missed visit can alter the course of care. Repeated outpatient reassessment without fungal testing gives the organism more time to persist, symptoms more time to accumulate, and clinicians more time to reinforce an incorrect diagnosis.
Why the Infection Is So Easy to Miss
The biology of Coccidioides explains much of the diagnostic drift. The fungi grow as mold in the environment, and infection begins when airborne arthroconidia are inhaled. Around 60% of infections are asymptomatic, but symptomatic disease often resembles a common respiratory illness closely enough to pass as something routine. Primary pulmonary disease is the dominant presentation, yet dissemination can occur through hematogenous or lymphatic spread to the skin, bones, joints, or central nervous system. Disseminated disease remains rare at about 1% of cases, but the risk rises sharply in immunocompromised patients.
Serologic testing can help, but it is not a perfect safeguard. Antibody testing has relatively high sensitivity, yet results can be negative early in the illness. Just as importantly, testing is often ordered only when a clinician already suspects coccidioidomycosis. If that suspicion never develops, the diagnostic cascade never begins.
The result is a familiar clinical trap: a patient with ongoing cough or fatigue receives antibiotics or an inhaler, returns unchanged, and only later enters the fungal diagnostic pathway.
Older Age, Rural Residence, and Pulmonary Disease Raised Risk
The analysis linked delayed diagnosis with several factors. Older age, rural residence, underlying pulmonary conditions, and prescriptions for antibiotics or inhalers were all significantly associated with delay. These associations make clinical sense. Older adults and patients with chronic lung disease often enter care with preexisting respiratory explanations already available, which can make a new fungal illness look like a flare of familiar disease. Rural residence may add another layer of friction, especially when endemic fungi are not top of mind outside recognized hot spots.
Antibiotic or inhaler prescribing may also function as a marker of diagnostic inertia. Once treatment begins for presumed bronchitis, pneumonia, or reactive airway disease, the next visit can become a continuation of the same working diagnosis rather than a reset.
The study did not frame diagnostic delay as an abstract epidemiologic event. It behaved like a common bedside failure mode: a syndrome was treated, but the cause was not named.
Claims Data Captured the Missed Opportunities
The investigators used a retrospective design based on health insurance claims and identified coccidioidomycosis using ICD-9-CM and ICD-10-CM diagnosis codes. Patients were required to have continuous enrollment for one year before the index diagnosis, and those diagnosed in 2001 were excluded. To estimate missed diagnostic opportunities, the analysis looked for prior visits where signs, symptoms, testing, or diagnoses were clinically plausible for underlying coccidioidomycosis and classified those encounters as symptomatically similar diagnoses, or SSDs.
Because missed opportunities cannot be observed directly in claims data, the team used a case-crossover strategy and a bootstrapping approach. The 13-week period before diagnosis served as the diagnostic opportunity window, while days 92 through 365 before diagnosis formed the crossover period used to estimate background rates of SSD visits. The methodological goal was straightforward: compare expected with observed symptom-associated visits and infer the excess that likely represented missed opportunities.
This approach does not create clinical certainty from administrative data, and it cannot replace chart review or bedside adjudication. Still, it gives a population-level estimate of how often the disease appears in the system before it is finally recognized.
Delayed Recognition Has Public Health Consequences
Coccidioidomycosis delay affects more than the individual patient. Timeliness of diagnosis matters for surveillance, outbreak detection, and source attribution. When diagnosis is delayed, the apparent timeline of infection becomes blurred, which can distort public health interpretation and weaken recognition of clusters or environmental exposure patterns.
That matters in an infection whose geographic range may be broader than traditionally assumed and may be expanding northward and eastward within the continental United States. Rising incidence only heightens the need for faster recognition. If the disease is increasing and clinicians still default to more familiar respiratory diagnoses, missed opportunities will continue to stack up before the fungal test is even considered.
The study’s bottom line is clinically direct: diagnostic delays are common, they cluster in outpatient care, and they are linked to recognizable risk factors. The remaining challenge is operational—teaching clinicians to think of coccidioidomycosis early enough to test for it before repeated empiric treatment becomes the default path.